Glonghui, Feb. 3 丨 Goldman Sachs published a report that upgraded the stock rating of Kangji Healthcare (9997.HK) from “neutral” to “buy”, and the target price soared 80% from HK$7.6 to HK$13.7, reflecting the high visibility of minimally invasive surgery (MIS) recovery after the Lunar New Year, the gradual return to normal patient flow, and the impact of centralized drug procurement may be manageable in the short term. The bank mentioned that the group's valuation is relatively attractive. The annual price-earnings ratio is 17.5 times, and the earnings per share forecast for 2022 to 2024 is expected to reach 29%.
大行评级 | 高盛：大幅上调康基医疗(9997.HK)目标价至13.7港元 评级升至买入
Big Bank Ratings | Goldman Sachs: Significantly Raised Kangji Healthcare's (9997.HK) Target Price to HK$13.7 Rating to Buy
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.